生物标志物发现
医学
蛋白质组学
生物标志物
移植
疾病
造血干细胞移植
髓系白血病
造血细胞
生物信息学
髓样
造血
计算生物学
临床试验
骨髓增生异常综合症
血液学
免疫学
转化研究
癌症
定量蛋白质组学
肿瘤科
组学
作者
Fotios V. Michelis,Ivan Pasic,Eleftherios P. Diamandis
标识
DOI:10.1097/moh.0000000000000951
摘要
PURPOSE OF REVIEW: Allogeneic hematopoietic cell transplantation (allo-HCT) is complicated by life-threatening conditions whose prompt diagnosis is essential yet frequently delayed. This review examines proteomic approaches to biomarker discovery for the most common posttransplant complications, emphasizing methodological reliability and translational status. RECENT FINDINGS: Proximity extension assay (PEA) and aptamer-based platforms now permit simultaneous quantification of thousands of proteins from microliter plasma volumes. For acute graft-versus-host disease (GVHD), validated plasma panels incorporating ST2 and REG3α have been established as prognostic tools, and a PEA discovery study in patients with acute myeloid leukemia identified a four-marker panel (SLAMF7, IL-1ra, BTN3A2, and DAB2) with an area under the curve of 0.90. For sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD), a PEA study of very severe cases identified multiple candidate proteins at diagnosis and four proteins whose serum levels declined during defibrotide treatment. Proteomic evidence for other complications remains sparse and early in development. SUMMARY: Most proteomic biomarker studies in allo-HCT derive from small single-center discovery cohorts. Multicenter validation, harmonized biobanking, and integration with clinical risk models are required before these biomarkers can enter transplant practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI